Peregrine Pharmaceut (PPHMP) 22.88 $PPHMP
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments
GlobeNewswire - Thu Jul 14, 3:05PM CDT
-- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 --
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 2016
GlobeNewswire - Thu Jul 07, 3:05PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company committed to improving patient lives by delivering high quality biological products through its contract development and manufacturing organization (CDMO) services and by advancing its novel R&D pipeline, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2016 on July 14, 2016 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the quarter and FY ended April 30, 2016 and review recent corporate developments.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Thu Jun 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (NasdaqPHM) (NasdaqPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
GlobeNewswire - Thu Jun 02, 7:05AM CDT
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Avid Bioservices to Exhibit at the 2016 BIO International Convention
Marketwired - Tue May 31, 7:05AM CDT
Showcasing Expanded Contract Manufacturing Capabilities From Early Stage Development to Commercialization; Onsite Access to Leading Biopharmaceutical Manufacturing Experts
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Marketwired - Mon May 23, 7:05AM CDT
Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
GlobeNewswire - Wed Apr 20, 7:05AM CDT
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells -
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Wed Mar 09, 7:22AM CST
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations--
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
GlobeNewswire - Mon Mar 07, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the company's prior manufacturing capacity, supporting up to an additional $40 million in revenue each year.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
GlobeNewswire - Thu Mar 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Thu Dec 10, 3:05PM CST
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial--
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Tue Dec 08, 3:44AM CST
The board of directors of Peregrine Pharmaceuticals (NasdaqPHMP) declared on Monday its quarterly dividend of USD0.65625 per share on its 10.50% Series E convertible preferred stock accruing from 1 October 2015 through 31 December 2015.
PPHMP: 22.88 (+0.66)
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015
GlobeNewswire - Thu Dec 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
GlobeNewswire - Mon Nov 23, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New York during the month of December. Steven W. King, president and chief executive officer, will participate in a panel discussion focused on cancer immunotherapy at Piper Jaffray's 27 Annual Healthcare Conference. Additionally, the company will be one of only 16 life science companies attending Roth Capital Partners' Immuno-Oncology Corporate Access Day.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
GlobeNewswire - Mon Nov 09, 7:05AM CST
- Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone -
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
GlobeNewswire - Thu Oct 15, 7:05AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The randomized Phase II trial will be conducted by Peregrine.
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments
GlobeNewswire - Thu Jul 14, 3:05PM CDT
-- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 --
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 2016
GlobeNewswire - Thu Jul 07, 3:05PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company committed to improving patient lives by delivering high quality biological products through its contract development and manufacturing organization (CDMO) services and by advancing its novel R&D pipeline, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2016 on July 14, 2016 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the quarter and FY ended April 30, 2016 and review recent corporate developments. PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Thu Jun 02, 3:00PM CDT
Peregrine Pharmaceuticals, Inc. (Nasdaq
PHM) (NasdaqPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock". PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses
GlobeNewswire - Thu Jun 02, 7:05AM CDT
- Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months -
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Avid Bioservices to Exhibit at the 2016 BIO International Convention
Marketwired - Tue May 31, 7:05AM CDT
Showcasing Expanded Contract Manufacturing Capabilities From Early Stage Development to Commercialization; Onsite Access to Leading Biopharmaceutical Manufacturing Experts
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences
Marketwired - Mon May 23, 7:05AM CDT
Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
GlobeNewswire - Wed Apr 20, 7:05AM CDT
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy Alone in TNBC Models; Combination Also Protects Against Re-Challenge With TNBC Tumor Cells -
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Wed Mar 09, 7:22AM CST
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations--
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
GlobeNewswire - Mon Mar 07, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the company's prior manufacturing capacity, supporting up to an additional $40 million in revenue each year. PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
GlobeNewswire - Thu Mar 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs. PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant. PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Thu Dec 10, 3:05PM CST
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial--
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals' board to pay USD0.65625 per preferred share dividend
M2 - Tue Dec 08, 3:44AM CST
The board of directors of Peregrine Pharmaceuticals (Nasdaq
PHMP) declared on Monday its quarterly dividend of USD0.65625 per share on its 10.50% Series E convertible preferred stock accruing from 1 October 2015 through 31 December 2015. PPHMP: 22.88 (+0.66)
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015
GlobeNewswire - Thu Dec 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs. PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences
GlobeNewswire - Mon Nov 23, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that the company will participate in two upcoming life science investor conferences being held in New York during the month of December. Steven W. King, president and chief executive officer, will participate in a panel discussion focused on cancer immunotherapy at Piper Jaffray's 27 Annual Healthcare Conference. Additionally, the company will be one of only 16 life science companies attending Roth Capital Partners' Immuno-Oncology Corporate Access Day. PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
GlobeNewswire - Mon Nov 09, 7:05AM CST
- Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone -
PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
GlobeNewswire - Thu Oct 15, 7:05AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine (PS)-targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The randomized Phase II trial will be conducted by Peregrine. PPHMP: 22.88 (+0.66), PPHM: 0.37 (-0.01)
